Nemaura Medical (NMRD) – Business Wire
-
Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet
-
Nemaura Medical Reports Initial Patient Data from UK NHS Miboko Study that Demonstrates Weight Loss in 100% of Participants
-
Nemaura Medical Appoints Justin Mclarney as Chief Finance Officer
-
Nemaura Medical to Provide US proBEAT™ Launch Update at The LD 500 Virtual Conference
-
Nemaura Medical to Present at The LD 500 Virtual Conference
-
Nemaura Medical Issues Presentation Pertaining to the use of Continuous Glucose Monitoring in COVID-19 Patients
-
Nemaura Medical Reports Results and Provides Business Update for the First Quarter Ended June 30, 2020
-
Nemaura Announces Correction and Pricing of Public Offering
-
Nemaura Announces Proposed Underwritten Public Offering
-
Nemaura Enters into Letter of Intent to Acquire Healthimation, LLC to Augment proBEAT™ Launch in the U.S.
-
Nemaura Medical to Integrate Activity Data From Third Party Wearable Devices to Its proBEAT™ App
-
Nemaura Medical Evaluates New Applications for Continuous Lactate Monitoring Using its BEAT™ Platform
-
Nemaura Medical Submits PMA Application for sugarBEAT® to U.S. FDA
-
Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2020
-
Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report
-
Nemaura Medical CEO to Participate in Investor Webinar and Q&A Session on July 7, 2020
-
Nemaura Participated as Guest Speaker at DiabetesMine™ D-Data ExChange 2020
-
Nemaura Medical to Present at Credit Suisse 2020 Virtual Diabetes Sessions
-
Nemaura Medical Set to Join the Russell 2000® Index and Russell 3000® Index
-
Nemaura Medical 2020 Stock Incentive Plan Approved at Annual General Meeting
-
Nemaura reports positive data from early head-to-head comparison with a major incumbent CGM Device
-
Nemaura Medical Announces Interview with CEO to Air on May 11
-
Nemaura Secures $5 Million Loan to Accelerate Commercial Strategy
-
Nemaura Plans To Launch Body-Worn Continuous Temperature Monitor (CTM) to Track Fever Caused by Viral Infections such as COVID-19
-
Nemaura to Launch New Digital Brand proBEAT™ in the USA, Targeting a Market of Over 100 Million Potential Users With Its Prescription-Free Consumer Wellness Glucose Monitoring Device and Digital Hea
-
Nemaura To Prepare for Launch of sugarBEAT® CGM In the U.S. Following FDA Feedback
-
Nemaura Medical Enters Into Multiple Verbal Non-Binding Agreements for its sugarBEAT® Platform
-
Nemaura Medical Launches sugarBEAT® App on Play Store Ahead of its Planned Commercial Launch of BEAT®diabetes Subscription Service
-
Nemaura Medical Plans Head-to-head Study with Major Glucose Monitoring System
Back to NMRD Stock Lookup
